Kymanox Expands Footprint, Capabilities with Acquisition of Europe-based anteris
By Alex Keown
February 16, 2023
Life sciences professional services company Kymanox Corporation expanded its European client service capabilities with the acquisition of anteris medical GmbH and anteris helvetia AG.
Kymanox provides its clients with expertise in multiple areas, including offering engineering, scientific, project management, quality assurance, human factors, testing and quality control, regulatory support, and more. The joint anteris team supports the pharmaceutical, biotech, and medical device industries globally by managing the development, quality, and registration of (drug/device and biologic/device) combination products, medical devices, and in-vitro diagnostic products.
The combination of the companies increases the service capabilities and reach across the life sciences industry in multiple markets. In addition to expanded offerings, the two European companies, known together as anteris, provide Kymanox with an expanded footprint in Europe, one in Germany and another in Switzerland. The Morrisville, N.C.-based company had previously established an office in Luxembourg.
Kymanox Chief Revenue Officer, Matt Neighoff, said the synergies from the merger with anteris provide the company with greater expertise in areas like European regulatory affairs, strategy, and pathways, as well as with biosimilar development and commercialization. The combination of teams offers Kymanox the opportunity to provide clients with multiple, seasoned experts on a variety of products and projects. “The expanded team allows for us to improve our development of solutions for our clients and to help get their products to patients and end users faster and with an unparalleled level of quality,” he noted.
Since its founding in 2004, Kymanox has grown exponentially. With its patient-forward focus, the company expanded its number of subject matter experts, end-to-end service offerings, and customer base. Kymanox customers include some of the largest pharmaceutical companies in the world, many mid-size biotechs, and even emerging start-ups.
The company was largely U.S. based but had a small footprint in Europe. Over time, customers let Kymanox know of increased need to have resources available outside of the U.S., particularly in the European Union, Neighoff said. As a result, Kymanox began to search for solutions and ultimately found anteris, a company that wanted to expand its own services in the United States anteris was similarly looking to expand their capabilities in North America.
“We saw a good chance for the companies to come together and both meet our corporate goals. Their DNA is extremely similar to ours because they too have a culture that focuses on helping clients get their products to market more efficiently. It gave us resources and expertise in the EU,” Neighoff said.
Jenny Wieboldt, an account manager with Kymanox, added the merger gave Kymanox’s existing European clients quick access to hands-on support from the anteris team.
“This gave us an opportunity to expand our services, and it’s already yielding benefits,” she said.
The merger is what Neighoff called a “100% fold-in,” with no expected layoffs. He said the level of expertise demonstrated by the anteris staff across different business practices meant they could be added into Kymanox without a reduction of workforce. The addition of anteris will provide Kymanox with an additional 30 employees. Prior to the merger, Kymanox employed about 275 workers across the United States including at its sites in RTP, where its headquarters is located, as well as Philadelphia, Chicago, Boston, and Luxembourg.
Not only was the experience level similar, but Neighoff also noted that both Kymanox and anteris shared a similar company culture. He said teams from both companies have the same work ethic and desire to help companies get medicines and medical devices in the hands of patients. Both companies eschew the word consultant, preferring to think of themselves as long-term partners and as an extension of the partners’ team. They entrench themselves with clients in order to “get things done,” Neighoff said.
“We really roll up our sleeves and go to clients and help them with their deliverables,” he added.
Stephen M. Perry, founder and Chief Executive Officer of Kymanox, said the combined resources of the companies will provide clients significant support for the development of vital modern medicines that will enable people to enjoy longer and healthier lives.
Even as the merger nears completion, Kymanox is already looking at expanding its knowledge-base in other aspects of the industry to further suit its clients. Among the areas the company is focused on are digital transformation and digital health.
- About the Author
- Latest Posts
Alex Keown is a freelance journalist who writes about a variety of subjects including the pharma, biotech, and life science industries. Prior to freelancing, Alex has served as a staff writer and editor for several publications.
